Ovarian cancer remains one of the most lethal cancers affecting women, largely because it is often diagnosed at an advanced stage and because resistance to platinum-based chemotherapy and PARP inhibitors eventually develops in most patients. High-grade serous ovarian cancer, the most common and aggressive subtype, has proven particularly stubborn, and survival rates have improved only marginally over recent decades. Against this backdrop, the idea of finding new uses for drugs that have already passed safety testing in humans, a strategy known as drug repurposing, has gained considerable traction. The new study demonstrates how modern computational tools can accelerate that process dramatically.

The research team, led by Yang Xiao, Wei Xia, and Yanan Song of Pudong Gongli Hospital and the Shanghai University of Medicine and Health Sciences, began by focusing on LY75, also known as CD205 or DEC205, a C-type lectin receptor best known for its role in antigen uptake by dendritic cells. Mining data from The Cancer Genome Atlas and the Human Protein Atlas, the investigators found that LY75 was significantly upregulated in ovarian cancer tissues compared with healthy tissue. More importantly, elevated LY75 expression correlated with shorter progression-free survival, marking the protein as both a potential biomarker of aggressive disease and an attractive therapeutic target.

With the target in hand, the team turned to structure-based virtual screening. Rather than testing thousands of compounds in the laboratory, they used the published crystal structure of the LY75 protein, deposited in the Protein Data Bank under the identifier 8K8H, as a template to computationally dock molecules from the TargetMol compound library. Docking predicts how well a small molecule fits into a binding pocket on a protein, but the researchers went considerably further. They applied MM/GBSA calculations, a method that estimates binding free energy by combining molecular mechanics forces with implicit solvent models, to rescore candidate poses. They also employed protein-ligand interaction fingerprints, or PLIF analysis, to compare the binding patterns of candidates against known interaction motifs, and ran ADMET predictions to filter out compounds likely to fail on absorption, metabolism, or toxicity grounds before any experiment was performed.

From this computational funnel, tepotinib emerged as the leading candidate. Tepotinib is an orally available small molecule approved in several countries for the treatment of non-small cell lung cancer harboring MET exon 14 skipping mutations, where it acts as a MET kinase inhibitor. Its appearance as a strong LY75 binder raised an obvious question: was any anti-cancer effect simply a consequence of MET inhibition? The team anticipated this concern and designed their study around it, measuring c-MET expression in their cell models, examining MET–LY75 co-expression patterns, and running parallel pharmacological controls with capmatinib, another selective MET inhibitor, to disentangle the two mechanisms.

The laboratory experiments delivered striking results. Tepotinib preferentially inhibited ovarian cancer cell lines with high LY75 expression, achieving half-maximal inhibitory concentrations, or IC₅₀ values, of 16.31 micromolar in SKOV3 cells and 18.91 micromolar in OVCAR-8 cells. In contrast, the drug showed markedly weaker activity against HO8910 cells, which express low levels of LY75, a dose-response pattern consistent with LY75 serving as the drug’s relevant target rather than an incidental one. To confirm a direct physical interaction, the researchers turned to surface plasmon resonance, a label-free optical technique that measures real-time binding between molecules immobilized on a sensor surface. The experiments confirmed that tepotinib binds LY75 directly, with a kinetic dissociation constant of 2.52 micromolar and a steady-state K_D of 3.74 micromolar, values indicating a specific and measurable interaction.

Perhaps the most intriguing mechanistic finding concerns what tepotinib does to the LY75 protein once bound. Treatment with the drug induced apoptosis in the sensitive cell lines, suppressed their migratory capacity, a process closely tied to metastatic spread, and downregulated LY75 protein levels. When the team probed how this downregulation occurred, they found that tepotinib accelerated LY75 degradation through a pathway that does not depend on the ubiquitin-proteasome system, the cell’s standard machinery for tagging unwanted proteins for destruction. Cycloheximide chase experiments, which block new protein synthesis and allow the decay rate of existing proteins to be measured, supported this conclusion. The identity of the alternative degradation route remains an open question, but the observation suggests tepotinib may engage lysosomal or autophagic pathways, a hypothesis that will require further work to confirm.

The in vivo evidence proved even more compelling. In mouse xenograft models implanted with SKOV3 ovarian cancer cells, oral administration of tepotinib markedly suppressed tumor growth, achieving a tumor inhibition rate of 79.6 percent. Analysis of the excised tumors showed reduced LY75 expression in the treated animals, consistent with the drug engaging its target in living tissue. All animal procedures were approved by the Institutional Animal Care and Use Committee of Shanghai Health Medical College and conducted in accordance with the ARRIVE guidelines for reporting animal research.

Crucially, the MET controls strengthened rather than weakened the case for LY75 as the operative target. Capmatinib, a structurally distinct MET inhibitor, failed to reproduce the full anti-tumor activity of tepotinib in the ovarian cancer models, and analyses of c-MET expression and MET–LY75 co-expression in patient datasets suggested that MET inhibition alone could not account for the magnitude of benefit observed. The authors therefore conclude that tepotinib’s effect in ovarian cancer reflects a genuine dual pharmacology, with LY75 binding and subsequent LY75 protein downregulation contributing substantially to its activity.

The implications of the study extend in several directions. First, it elevates LY75 from an immunological curiosity to a candidate therapeutic target in ovarian cancer, a protein whose abundance in tumors and association with poor prognosis make it a marker worth tracking clinically. LY75 has already attracted attention in oncology as a target for antibody-drug conjugates, given its presence on the surface of certain tumor cells and its efficient internalization, and the new findings add a small-molecule dimension to that conversation. Second, the work offers a template for computational drug repurposing: crystal-structure-guided docking, energy-based rescoring, interaction fingerprinting, and ADMET filtering followed by rigorous biochemical and in vivo validation. The approach identifies candidates in silico in a fraction of the time and cost of conventional screening campaigns.

Third, and most immediately, the results argue for clinical exploration of tepotinib in ovarian cancer, particularly in patients whose tumors express high levels of LY75. Because the drug is already approved and its safety profile in humans is documented, the path from laboratory finding to clinical trial is potentially shorter than for a de novo compound. The micromolar potencies observed in cell culture are modest by the standards of modern targeted therapy, and patients would likely require careful dosing studies, biomarker-based selection, and possibly drug combinations to translate the xenograft results into human benefit. Questions also remain about whether the ubiquitin-proteasome-independent degradation mechanism operates identically in human tumors and about the precise structural features of the tepotinib–LY75 interaction that could be optimized in next-generation analogs.

The study is not without limitations, as its authors acknowledge. The work relies on cell lines and xenografts rather than patient-derived models, and the correlation between LY75 expression and drug sensitivity, while suggestive, has been established across only a handful of cell lines. Prospective validation in patient-derived xenografts and organoids, ideally stratified by LY75 expression, would sharpen the biomarker hypothesis considerably. Nonetheless, the convergence of computational prediction, biochemical confirmation, mechanistic insight, and animal efficacy data makes this one of the more complete preclinical repurposing cases published for ovarian cancer in recent memory.

For a disease in which the therapeutic arsenal has expanded slowly and resistance is nearly universal, the prospect that a drug already sitting on pharmacy shelves could be redirected against a newly validated molecular target is the kind of story that resonates far beyond the laboratory. If follow-up studies and early-phase trials bear out these findings, tepotinib’s second act may prove more consequential than its first, and LY75 may take its place among the actionable targets of precision oncology.

Colorectal cancer remains one of the most frequently diagnosed and deadliest malignancies worldwide, ranking near the top of global tables for both incidence and mortality. When the disease is discovered early, surgery can be curative, but once tumor cells have spread to regional lymph nodes or distant organs, systemic chemotherapy becomes the backbone of treatment. The FOLFOX regimen—oxaliplatin combined with 5-fluorouracil and leucovorin—has anchored first-line therapy for advanced colorectal cancer for years, shrinking tumors, delaying recurrence, and prolonging survival. Its Achilles heel is acquired chemoresistance: many tumors respond at first, then evolve the ability to survive both drugs, leaving oncologists with a shrinking arsenal. Deciphering the machinery that confers this resilience has become one of the most urgent quests in gastrointestinal oncology, because a resistance mechanism, once identified, can itself be converted into a therapeutic target.

The enzyme now implicated in that process belongs to a family of related enzymes known as polypeptide N-acetylgalactosaminyltransferases, or GALNTs, of which the human genome encodes roughly twenty functional members. These enzymes reside in the Golgi apparatus, the cell’s protein-processing warehouse, where they initiate O-GalNAc glycosylation: the attachment of the sugar N-acetylgalactosamine onto serine or threonine amino acids within newly made proteins. Far from being a cosmetic modification, this mucin-type glycosylation alters how proteins fold, how they travel to the cell surface, how long they persist there, and how powerfully they transmit signals. Over the past decade, cancer researchers have learned that individual GALNT members can behave as oncogenic drivers, and GALNT5 in particular has a growing rap sheet. An earlier study linked it to resistance against FOLFIRINOX—the pancreatic cancer analog of FOLFOX—in pancreatic ductal adenocarcinoma, operating through a MYH9/NOTCH/DNA damage response axis. Whether the same enzyme played a comparable double role in colorectal cancer, driving both malignant progression and resistance to oxaliplatin and 5-fluorouracil, had not been resolved.

To close that gap, the team combined computational and experimental approaches. Integrated bioinformatics analyses first flagged GALNT5 expression across colorectal cancer cell lines, and the finding was confirmed with RNA sequencing, quantitative reverse-transcription PCR, and Western blotting, using the normal colonic epithelial cell line NCM460 as a baseline. The researchers then engineered two chemoresistant daughter lines from the colorectal cancer cell line LoVo: one chronically exposed to oxaliplatin until it became resistant, designated LoVo/L, and another trained on 5-fluorouracil, designated LoVo/5FU. RNA sequencing of these models mapped the signaling pathways and effector genes that bend when GALNT5 activity changes. Cell proliferation was quantified with CCK-8 assays, invasion was measured in Transwell chambers, and apoptosis was monitored as GALNT5 levels were manipulated. Because GALNT enzymes work by chemically modifying proteins rather than altering genes directly, the team also deployed lectin-based assays capable of detecting the sugar additions themselves—a methodological decision that would prove pivotal for the mechanistic experiments. Finally, the pharmacology was tested with 740Y-P, a synthetic agonist that switches on phosphoinositide 3-kinase, allowing the team to interrogate whether the PI3K pathway sat downstream of the enzyme.

The expression screen produced a clear verdict: GALNT5 is significantly upregulated in colorectal cancer cell lines compared with normal colonic epithelium. More importantly, that overexpression was not a passive byproduct of malignancy. When the researchers silenced GALNT5, the cancer cells’ behavior shifted on every metric tested. Proliferation slowed markedly, the capacity to invade through Transwell membranes dropped, and apoptosis increased in both the parental cells and the drug-resistant derivatives. In effect, GALNT5 was acting as a tumor-promoting gene, sustaining the proliferative drive, motility, and survival advantages that define aggressive disease. Crucially, the enzyme’s grip extended to the resistant sublines as well: removing GALNT5 weakened even cells that had already learned to endure chemotherapy. Because the parental and resistant lines are otherwise genetically matched, the parallel effects argue that GALNT5 is functionally upstream of both the aggressive growth phenotype and the resistance phenotype, not merely a passenger carried along during tumor evolution.

The pivotal experiments concerned the resistant cells themselves. When GALNT5 was knocked down in LoVo/L and LoVo/5FU cells, their sensitivity to oxaliplatin and 5-fluorouracil rebounded—the drugs regained their capacity to kill cells they had previously failed to eliminate. That observation alone would have been notable, but the team went further with a decisive control. They treated the GALNT5-silenced, drug-vulnerable cells with 740Y-P, a small-molecule agonist that directly activates phosphoinositide 3-kinase (PI3K), the enzyme that ignites the Akt survival pathway. The protective effect of losing GALNT5 evaporated: with PI3K forcibly reactivated, the cells clawed back much of their resistance to both drugs. The rescue experiment established that GALNT5 works through the PI3K/Akt axis rather than through some parallel route, and it placed a well-mapped, heavily drugged signaling cascade at the heart of the resistance mechanism.

The remaining question was how an enzyme inside the Golgi reaches a signaling pathway in the cytoplasm. The answer emerged from lectin pull-down assays using VVL, or Vicia villosa lectin, a plant-derived protein with a strong affinity for terminal N-acetylgalactosamine residues. By using VVL to fish out sugar-decorated proteins, the researchers confirmed that GALNT5 directly mediates O-GalNAc glycosylation of the epidermal growth factor receptor, or EGFR—the membrane receptor that serves as a master upstream activator of PI3K/Akt signaling. Glycosylation is known to shape how growth-factor receptors mature, localize, and signal, and the new data show that GALNT5’s sugar additions potentiate EGFR’s pro-growth output. Downstream, the team documented a second, equally consequential effector: depletion of GALNT5 caused downregulation of ABCC1, an ATP-binding cassette transporter also called multidrug resistance-associated protein 1, whose function is to pump foreign molecules—including many chemotherapeutics—out of the cell. ABCC1 overexpression is a classic textbook mechanism of multidrug resistance, and the finding that a glycosyltransferase controls it in vitro and in vivo ties the sugar code directly to the drug-export machinery. The in vivo arm of the study, conducted under approval from an institutional animal care committee in accordance with the Declaration of Helsinki, confirmed that GALNT5 depletion suppressed ABCC1 in living tumor models as well as in culture dishes.

The study lands in a research landscape that is rapidly converging on the same theme from multiple angles. The earlier pancreatic cancer work established GALNT5 as an oncogenic driver of FOLFIRINOX resistance through a different downstream axis, implicating the cytoskeletal protein MYH9, the NOTCH developmental pathway, and the DNA damage response. Other family members tell similar stories: GALNT2, targeted by the microRNA miR-139-5p, has been shown to promote proliferation in clear cell renal cell carcinoma by interfering with LATS2 activation. A separate multi-omics analysis has even cast post-translational modification networks—including glycosylation—as central regulators of colorectal cancer progression and immune evasion. What emerges across these reports is that GALNT enzymes are not passive housekeepers of protein decoration; in cancer, individual members can recalibrate receptor signaling, cell-cycle machinery, and drug-response pathways simultaneously. The colorectal study adds a mechanistic template that is especially clean: sugar modification of a receptor tyrosine kinase at the top, transporter deregulation at the bottom, and a single survival pathway connecting the two.

For clinicians and drug developers, the appeal of GALNT5 is its potential double utility. As a biomarker, measuring GALNT5 expression in tumor tissue could, in principle, flag patients whose cancers are biologically primed to resist oxaliplatin and 5-fluorouracil before the first infusion, allowing oncologists to select alternative regimens or plan intensification from the outset. As a target, the enzyme offers an intervention point upstream of two heavily validated pathways—PI3K/Akt signaling and the ABCC1 drug pump—meaning that a GALNT5 inhibitor could, in theory, suppress growth and dismantle chemoresistance at the same time. Combination strategies that pair such an inhibitor with existing FOLFOX chemotherapy are the most obvious translational path. Important caveats remain, however. The study, published as an open-access early-release article that is citable ahead of the final version of record, rests on cell lines, xenograft evidence, and molecular assays rather than patient trials. GALNT enzymes also serve essential glycosylation functions in healthy tissues, particularly in mucin-producing epithelia, so any therapeutic inhibition would need to demonstrate an acceptable safety window.

What the study ultimately delivers is a complete, testable chain of causation. An overexpressed Golgi enzyme glycosylates EGFR; hyperactive EGFR ignites PI3K/Akt signaling; and that pathway simultaneously fuels proliferation and invasion while sustaining the ABCC1 pump that expels oxaliplatin and 5-fluorouracil from the cell. Every node in the chain is now a candidate point of intervention, and the weakest link—GALNT5 itself—has the distinction of sitting at the very top. The research was funded by the Jilin Provincial Special Project for Health Research Talents and was led by co-first authors Qiong Wu and Liehao Yang, with Changmiao Wang as corresponding author, drawing on investigators from the First Affiliated Hospital of Dalian Medical University and the China-Japan Union Hospital of Jilin University. If subsequent studies confirm that inhibiting GALNT5 can resensitize human tumors as reliably as it does laboratory models, one of colorectal cancer’s most resilient survival tricks—written, improbably, in sugar—may finally become one of its most exploitable weaknesses.

Autophagy, meaning “self-eating,” is a tightly regulated process that allows cells to break down damaged proteins, defective mitochondria, and other unwanted components. The material is enclosed within structures called autophagosomes, which later fuse with lysosomes containing digestive enzymes. The resulting molecular building blocks can be reused for energy and repair. Under normal conditions, autophagy protects cells from stress. In cancer, however, the same survival mechanism can become a powerful defense against chemotherapy.

Cisplatin resistance in gastric cancer does not arise from a single molecular defect. Tumor cells may increase their ability to repair cisplatin-induced DNA damage, reduce the accumulation of the drug, alter pathways that control apoptosis, or reshape the surrounding tumor microenvironment. Changes in cellular metabolism and signaling can further support survival. According to the review, autophagy intersects with many of these mechanisms, helping cancer cells withstand the metabolic and genetic damage caused by treatment.

The relationship between autophagy and cancer is complex because the process can have opposite effects. Excessive or uncontrolled autophagy may contribute to a form of cellular destruction, particularly when cancer cells are exposed to severe stress. More commonly, however, moderate autophagy acts as a protective response. By removing damaged mitochondria and supplying nutrients during treatment, it can prevent the accumulation of toxic cellular components and delay the onset of apoptosis. The biological outcome therefore depends on the intensity, timing, and molecular context of autophagy within each tumor.

The review discusses several existing medicines that could be repurposed or combined with cisplatin to manipulate this process. Chloroquine, for example, interferes with the function of lysosomes and can block the later stages of autophagy, preventing cancer cells from completing the recycling cycle. Metformin, a widely used diabetes drug, may influence autophagy through energy-sensing pathways such as AMP-activated protein kinase and the mammalian target of rapamycin. Other medicines considered include diclofenac, omeprazole, ubenimex, and bortezomib, each of which may affect autophagy or related stress-response networks through distinct mechanisms.

The review also highlights natural compounds with potential activity against cisplatin-resistant gastric cancer. Glycyrrhizin, baicalein, red ginseng polysaccharide, and α-mangosteen are among the candidates discussed. Laboratory studies suggest that such compounds may alter oxidative stress, inflammatory signaling, mitochondrial function, or autophagy-related proteins. However, their presence in a review does not mean that they are proven clinical treatments. Their effectiveness, optimal dosage, pharmacological behavior, and safety alongside cisplatin will require careful validation in animal studies and controlled human trials.

At the molecular level, researchers are investigating the signaling networks that determine whether autophagy protects or eliminates tumor cells. These include pathways controlled by mTOR, AMPK, PI3K, AKT, and other regulators of cellular growth and metabolism. Transcription factors, microRNAs, and proteins involved in autophagosome formation may also influence treatment response. Mapping these networks could allow researchers to identify tumors that rely heavily on protective autophagy and selectively target that vulnerability, rather than applying the same autophagy-modifying strategy to every patient.

The authors further describe the possibility of combining autophagy modulation with immunotherapy, radiotherapy, and precision medicine. Autophagy can influence the release of tumor antigens, immune-cell activity, and the inflammatory environment surrounding a tumor, potentially affecting how effectively the immune system recognizes malignant cells. Radiation can also generate cellular damage that activates autophagy, raising the possibility that carefully timed inhibition or stimulation could improve treatment. Such combinations would need to be designed with precision, since blocking autophagy in healthy tissues or immune cells could produce unwanted effects.

The central message of the review is that autophagy is neither simply a friend nor an enemy of cancer therapy. Its role changes according to tumor genetics, treatment conditions, and the stage of the cellular response. Future strategies may rely on biomarkers that reveal whether autophagy is operating as a survival mechanism in an individual patient’s tumor. By matching cisplatin with the right autophagy-modulating agent, researchers hope to prevent cancer cells from repairing themselves, maintaining energy supplies, and escaping programmed cell death. The approach remains under investigation, but it offers a scientifically grounded strategy for confronting one of gastric cancer’s most persistent clinical challenges.

Subject of Research: Autophagy as a therapeutic target for cisplatin-resistant gastric cancer.

Article Title: Autophagy as a therapeutic target for cisplatin-resistant gastric cancer

Web References: Genes & Diseases: https://www.sciencedirect.com/journal/genes-and-diseases ; DOI: https://doi.org/10.1016/j.gendis.2025.101992

References: Luling Wei, Yingfei Zhou, Jiashuo Li, Hongzhao Qi, Shasha Wang, “Autophagy as a therapeutic target for cisplatin-resistant gastric cancer,” Genes & Diseases, Volume 13, Issue 5, 2026, Article 101992. DOI: 10.1016/j.gendis.2025.101992

Image Credits: Genes & Diseases

Keywords: gastric cancer, cisplatin resistance, autophagy, chemotherapy, cancer therapy, chloroquine, metformin, precision medicine, apoptosis, molecular oncology

The study, published in Cancer Letters, identifies MDA-9/Syntenin—also known as syndecan-binding protein 1, or SDCBP—as a major regulator of aggressive HNSCC biology. MDA-9 is a scaffold protein, meaning that it helps organize molecular partners inside and outside cells rather than acting as a conventional enzyme. By bringing signaling proteins into the correct position, it can influence tumor-cell migration, invasion, angiogenesis and immune suppression. The VCU-led team found that MDA-9 is also important for maintaining cancer stem cells, a small but powerful population capable of renewing itself and generating new tumor cells.

The researchers tested IVMT-Rx-4, a small-molecule inhibitor designed to interfere with MDA-9/Syntenin’s interactions with partner proteins. In preclinical models of HNSCC, the compound sharply restricted tumor growth and metastasis, in some cases leaving treated animals tumor-free. The experiments did not reveal observable toxicity, an important result because a drug that attacks tumor-promoting machinery must still preserve the functions of healthy tissues. The findings indicate that MDA-9 may be unusually suitable for therapeutic targeting because laboratory models lacking the protein have shown no obvious physiological defects while displaying increased resistance to metastatic spread.

The compound’s most important effect appeared to involve the cancer stem-cell compartment. Unlike the bulk of a tumor, cancer stem cells can remain dormant, repair damage and recreate a diverse population of malignant cells after treatment. Their persistence is one reason cancers can return after apparently successful therapy. The VCU team used molecular and functional assays to show that MDA-9 supports stem-cell properties in HNSCC and that IVMT-Rx-4 can disrupt those properties. In effect, the drug targets the regenerative core of the tumor rather than merely reducing the visible mass of cancer cells.

One molecular indicator of this effect was BMI1, a transcriptional regulator associated with stemness and tumor-maintaining capacity in HNSCC. IVMT-Rx-4 suppressed BMI1 and reduced the ability of cancer cells to form new tumor populations. This result is significant because conventional chemotherapy may eliminate rapidly dividing cells while leaving behind resistant stem-like cells. The surviving population can then repopulate the tumor and acquire additional protective features. By interfering with MDA-9-dependent signaling, IVMT-Rx-4 appeared to prevent this rebound in experimental systems.

The study also reported evidence that the inhibitor can counter cisplatin resistance. When HNSCC cells were exposed to cisplatin, the proportion of stem-like, drug-tolerant cells increased. Treatment with IVMT-Rx-4 blocked that enrichment and, in some experiments, reversed characteristics associated with an already resistant state. Combining the experimental inhibitor with standard chemotherapy therefore produced a more pronounced anticancer effect than either approach alone. Although these results remain preclinical, they raise the possibility that MDA-9 inhibition could be used alongside existing therapy to prevent resistance from emerging or to restore sensitivity after it has developed.

MDA-9’s potential importance extends beyond HNSCC. Earlier work by Paul B. Fisher and colleagues first cloned the gene and established its role in cancer progression. The protein has since been linked to multiple stages of metastasis, including the ability of tumor cells to leave a primary lesion, survive in the bloodstream, attach to distant tissues and stimulate the formation of new blood vessels. MDA-9 also contributes to an immunologically “cold” tumor microenvironment, in which immune cells are less able to recognize or destroy malignant cells. These broad functions help explain why the protein is being investigated in prostate, breast, brain and liver cancers as well as head and neck tumors.

IVMT-Rx-4 was developed by InVaMet Therapeutics, a company co-founded by Fisher, and is an intermediate synthesis product related to the earlier compound PDZ1i. According to the researchers, the newer molecule has improved water solubility, lower cellular efflux and enhanced sensitivity compared with unmodified PDZ1i, characteristics that may improve its drug-like behavior. The team is now exploring whether IVMT-Rx-4 can be formulated as an oral medicine. Additional studies will be required to determine its absorption, metabolism, dosing, long-term safety and effectiveness in larger animal models before human trials can be considered.

The work involved investigators from VCU Massey Comprehensive Cancer Center, the VCU Institute of Molecular Medicine, the VCU Center for Drug Discovery and the departments of Medicinal Chemistry and Cellular, Molecular and Genetic Medicine, along with collaborators at Cornell University and Virginia Tech. Senior author Paul B. Fisher said the research identifies a direct drug target and establishes IVMT-Rx-4 as a promising chemical probe for developing new cancer treatments. Jiong Li, the study’s co-corresponding author, emphasized that metastatic head and neck cancer remains extremely difficult to manage and that therapies capable of preventing spread and overcoming resistance are urgently needed.

The findings do not yet demonstrate that IVMT-Rx-4 can cure patients, and no FDA-approved treatment currently eliminates all cancer stem cells. However, the results offer a mechanistic explanation for how a single molecular target might affect tumor growth, metastasis, stem-cell maintenance and chemotherapy resistance at the same time. If future studies confirm the compound’s safety and therapeutic activity, MDA-9/Syntenin inhibition could become a new strategy for treating aggressive HNSCC and potentially other cancers driven by the same metastatic and drug-resistant pathways.

Subject of Research: MDA-9/Syntenin inhibition, cancer stem cells, metastasis and chemotherapy resistance in head and neck squamous cell carcinoma

Article Title: Targeting MDA-9/syntenin-1 (SDCBP) as a strategy to eliminate head and neck squamous cell carcinoma stem cells

News Publication Date: 27 June 2026

Web References: https://www.sciencedirect.com/science/article/pii/S0304383526004568?via%3Dihub; https://www.masseycancercenter.org/news/2026/innovative-targeted-therapy-halts-prostate-cancer-spread-to-the-bone/; https://www.masseycancercenter.org/news/massey-scientists-awarded-r01-to-investigate-treatment-options-for-advanced-prostate-cancer/

References: Cancer Letters, DOI: 10.1016/j.canlet.2026.218692

Image Credits: VCU

Keywords: Head and neck cancer, head and neck squamous cell carcinoma, HNSCC, MDA-9, Syntenin, SDCBP, IVMT-Rx-4, cancer stem cells, chemotherapy resistance, cisplatin, metastasis, targeted cancer therapy, small-molecule inhibitors

The team focused on CUDC-907, a dual inhibitor that combines PI3K and HDAC blockade. PI3K pathway activity can support growth and resistance, while HDAC inhibition can reshape gene expression and stress responses. Together, these actions were tested for their ability to slow GBM proliferation and weaken the mechanisms tumors use to withstand DNA damage.

In cultured GBM cells, the investigators used cell-cycle and apoptosis assays to track how CUDC-907 changes cellular fate. The results showed a pronounced arrest in the G0/G1 phase, consistent with impaired cell-cycle progression. Molecular profiling further supported this shift, revealing decreased levels of core cycle and oncogenic regulators, alongside increased activity of a checkpoint protein.

To connect these phenotypes to specific signaling and transcriptional outputs, the study measured key proteins including MYC and cyclin-dependent kinases such as CDK2 and CDK4. CUDC-907 reduced MYC-driven expression programs while increasing p21, a checkpoint mediator known to restrain cell-cycle advancement when stresses accumulate.

Beyond proliferation, the researchers evaluated tumor aggressiveness traits relevant to invasion. They reported that CUDC-907 reduced migration and invasion-associated markers, including N-Cadherin, MMP2, and vimentin—molecular changes that suggest a weakened metastatic phenotype.

The central translational question was whether CUDC-907 can sensitize GBM to TMZ. Across multiple experimental platforms, including organoid systems and orthotopic mouse models, the combination produced a synergistic anti-tumor effect rather than simply additive inhibition.

Mechanistically, TMZ normally kills cells by damaging DNA, but resistant GBM can repair that damage. Here, CUDC-907 intensified DNA double-strand break indicators and increased PARP1 cleavage, while broadly disrupting DNA repair responses. The study also highlighted alterations in JAK-STAT signaling, linking pathway modulation to impaired repair and heightened chemotherapy vulnerability.

Overall, the findings position CUDC-907 as a promising pharmacological strategy to counter TMZ resistance. By concurrently suppressing MYC-associated cell-cycle control and undermining DNA damage repair, the dual PI3K/HDAC approach may help convert resistant GBM into a more treatable state.

Subject of Research: Glioblastoma chemoresistance; targeted PI3K/HDAC inhibition; TMZ sensitization

Article Title: CUDC-907 inhibits glioblastoma and enhances glioblastoma sensitivity to temozolomide by inhibiting DNA damage repair

References: 10.1016/j.gendis.2025.101948

Image Credits: Credit: Chencheng Fang, Pan Gou, Dandan Zhang, Xuanxuan Wu, Xiao Li, Man Li, Lu Gan, Jinjin Luo, Hongjuan Cui, Man Xu, Ping Liang

Keywords: glioblastoma, CUDC-907, PI3K, HDAC, temozolomide, TMZ resistance, MYC, p21, DNA damage repair, γ-H2AX, PARP1, JAK-STAT, organoids, orthotopic mouse model

AML’s bleak prognosis often stems from the cancer cells’ ability to adapt and evade frontline treatments, especially combinations of hypomethylating agents and venetoclax. The TP53 gene mutation, in particular, confers a formidable therapeutic resistance by disabling the cell’s natural damage control mechanisms and fostering unchecked proliferation. NTX-301, however, retains potent activity in AML models that have developed resistance to conventional therapies, effectively reducing leukemia cell survival in experimental and patient-derived xenograft models.

What sets NTX-301 apart is its selective epigenetic reprogramming, which targets the Hippo signaling pathway — a crucial regulator of cell growth and organ size that has recently been implicated in cancer progression and treatment resistance. Unlike traditional hypomethylating agents that broadly alter DNA methylation patterns, NTX-301 precisely modulates the expression of genes within the Hippo pathway. This modulation includes enhancement of tumor-suppressor components and suppression of YAP, a protein associated with cancer cell survival and stemness.

The activation of the Hippo pathway by NTX-301 not only curtails leukemia cell growth but also dismantles key resistance mechanisms, explaining its efficacy in refractory AML. Moreover, when combined with venetoclax, NTX-301 produces synergistic effects that extend beyond bulk leukemia cells to target leukemia stem and progenitor cells, which are typically responsible for relapse and disease persistence.

These insights reveal a dual therapeutic strategy: reactivating suppressed tumor-inhibiting pathways while simultaneously disabling cellular survival programs. The implications for clinical translation are significant, as this approach may offer a much-needed option for patients with relapsed AML, venetoclax-resistant disease, and those harboring TP53 mutations — cohorts historically limited in treatment choices.

Further research is warranted to validate NTX-301’s efficacy in clinical settings and to identify biomarkers predictive of response. The study’s authors highlight the potential of epigenetic therapies that specifically engage the Hippo pathway as an innovative frontier to overcome resistance, offering new hope against a lethal and stubborn disease.

This research marks a pivotal moment in leukemia therapeutics, opening avenues that blend molecular precision with overcoming adaptive resistance. As NTX-301 advances through further development, it holds the promise of transforming outcomes in AML, one of the most aggressive blood cancers currently confronting patients and clinicians alike.

Subject of Research: Acute Myeloid Leukemia, Epigenetic Therapy, Hippo Signaling Pathway
Article Title: The novel hypomethylating agent NTX-301 reprograms epigenetic and Hippo signaling pathways and exhibits pre-clinical activity in venetoclax-resistant and TP53-mutant AML
News Publication Date: July 13, 2026
Web References: https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-4843
Image Credits: The University of Texas MD Anderson Cancer Center
Keywords: Acute Myeloid Leukemia, Epigenetic Therapy, NTX-301, Treatment Resistance, TP53 Mutation, Hippo Pathway, Venetoclax Resistance, Leukemia Stem Cells

Nitrosative stress involves an overproduction of nitric oxide (NO) molecules that disrupt normal cellular functions and promote tumor survival and invasiveness. The team focused on an experimental compound, BA-101, which selectively inhibits neuronal nitric oxide synthase (nNOS), a key enzyme driving this pathological process. By blocking nNOS, BA-101 dramatically curbs the nitrosative stress that enables glioblastoma cells to evade chemotherapy.

In preclinical models, the combination of BA-101 with temozolomide exhibited a remarkable synergy, substantially slowing tumor growth and reducing the cancer cells’ capacity to invade neighboring tissues. The treatment not only lowered molecular markers of nitrosative stress but also induced apoptosis, or programmed cancer cell death—effects that neither drug achieved alone to the same extent.

“Temozolomide resistance remains a significant hurdle in effective glioblastoma treatment,” explained Prof. Haitham Amal, senior author of the study. “Our findings indicate that targeting nitrosative stress can re-sensitize tumors to chemotherapy, potentially transforming how we approach this deadly disease.”

This innovative therapeutic avenue moves beyond conventional strategies that solely aim to replace ineffective drugs. Instead, it addresses the underlying biochemical environment that grants cancer cells their resilience. By disabling the nitrosative stress pathway, BA-101 disrupts the tumor’s defense mechanisms, amplifying the cytotoxic impact of TMZ.

While the results are promising, the team stresses that BA-101 is still in the experimental stage. Extensive preclinical validation and subsequent clinical trials will be essential to evaluate its safety and efficacy in human patients. The compound, licensed to the biotech company NeuroNOS—which was co-founded by Prof. Amal—is poised for further development as a potential first-in-class treatment for resistant glioblastoma.

This research not only opens a new frontier in brain cancer therapy but also exemplifies how a deeper understanding of tumor biology can lead to innovative treatments. If successful in clinical settings, this combination therapy could significantly improve survival outcomes for patients battling temozolomide-resistant glioblastoma, a cancer that currently offers very limited hope.

As the study progresses, it may pave the way for novel pharmacological interventions that target similar resistance mechanisms across different cancers, marking a vital turning point in oncology.

Subject of Research: Cells
Article Title: Targeting Temozolomide-Resistant Glioblastoma: Therapeutic Potential of Neuronal Nitric Oxide Synthase Inhibitor
News Publication Date: July 15, 2026
Web References: http://dx.doi.org/10.1002/cam4.72067
Image Credits: Igor Farberov
Keywords: Glioblastoma, brain cancer, chemotherapy resistance, nitrosative stress, neuronal nitric oxide synthase inhibitor, temozolomide, cancer therapy, drug resistance

Multiple myeloma is a complex hematologic malignancy characterized by the proliferation of malignant plasma cells within the bone marrow. Despite advances in treatment, relapsed myeloma patients often encounter resistance to standard-of-care therapies such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies like daratumumab. The urgent need for innovative approaches has paved the way for immunotherapy modalities that harness and direct the body’s immune system to target myeloma cells more effectively.

Teclistamab represents a paradigmatic shift in the modality of treatment. As a bispecific antibody, it simultaneously binds to two distinct antigens: the B-cell maturation antigen (BCMA) found on malignant myeloma cells, and CD3 receptors on T cells. This dual binding mechanism redirects cytotoxic T cells to engage and eliminate myeloma cells with precision, overcoming some immune evasion tactics employed by cancer cells. This targeted immunological attack is designed to enhance tumor killing while minimizing damage to healthy tissues.

The MajesTEC-9 trial enrolled 593 patients across 24 countries, each with multiple myeloma that had progressed following one to three prior lines of therapy. Importantly, a significant proportion of these individuals had become refractory to existing therapies—including lenalidomide and daratumumab—underscoring the urgent unmet need for more potent treatment options. The study rigorously compared teclistamab monotherapy against standard care regimens currently available in clinical practice.

Results from this robust international study were striking. Nearly 70% of patients administered teclistamab remained progression-free at 18 months, a substantial improvement over the 27% progression-free rate observed in the standard therapy cohort. Beyond mere disease stabilization, approximately two-thirds of teclistamab-treated patients achieved complete remission. Of critical importance, many patients reached minimal residual disease negativity, as defined by highly sensitive detection methodologies, indicating an unprecedented depth of response.

These outcomes are not only statistically significant but translate into meaningful clinical benefit for patients. Extended remission duration can alleviate the symptom burden associated with multiple myeloma, including bone pain, anemia, and renal insufficiency, thereby substantially improving quality of life. Prolonged disease control also reduces the likelihood of rapid relapse and the need for multiple sequential lines of toxic chemotherapy, which can diminish functional status and survival.

However, the powerful immunostimulatory effects of teclistamab do present therapeutic challenges. Activation of the immune system can simultaneously impair normal protective mechanisms, resulting in a higher incidence of infections during the initial six months of treatment. Clinical teams mitigate this risk by vigilant monitoring and implementing prophylactic antiviral and antibiotic regimens. Additionally, patients may receive immunoglobulin infusions to bolster their defenses if antibody levels drop below critical thresholds.

This trial not only solidifies teclistamab’s potential in later lines of therapy but opens avenues for investigating bispecific antibodies earlier in the treatment paradigm. Administering immunotherapy at earlier stages may capitalize on more intact immune systems, potentially enhancing efficacy and moving closer to the goal of durable disease eradication or functional cure.

Dr. C. Ola Landgren, chief of the Sylvester Myeloma Institute, emphasizes the transformational nature of this therapy. His insight reflects decades of evolution in myeloma care, progressing from reliance on cytotoxic chemotherapy to sophisticated immune-based strategies that leverage molecular targeting and immunologic precision. The journey towards curative regimens for multiple myeloma is accelerating, and teclistamab stands at the forefront of this revolution.

The convergence of cutting-edge antibody engineering and immuno-oncology exemplified by teclistamab heralds a new era of personalized treatment for myeloma patients. This progress also exemplifies the critical importance of international collaboration in clinical research, bringing together diverse populations and expertise to rigorously evaluate novel agents and translate findings into clinical practice.

As the scientific community continues to unravel the intricate biology of myeloma and immune interactions, agents like teclistamab are poised to fundamentally alter disease trajectories and patient outcomes. Future investigations will determine optimal combinations, sequencing, and patient selection to maximize therapeutic index while maintaining safety.

In summary, the successful demonstration of teclistamab’s efficacy in heavily pre-treated multiple myeloma patients represents a landmark achievement. By delivering potent, targeted immunotherapy without reliance on traditional chemotherapy, it offers not only hope for longer survival but a pathway to deeper, sustained remissions that could redefine standards of care worldwide. Ongoing research efforts inspired by these results promise to extend these benefits to patients at various stages of the disease continuum, moving closer to the long-sought goal of a cure.

Subject of Research: Teclistamab immunotherapy in relapsed multiple myeloma

Article Title: Teclistamab Monotherapy in Multiple Myeloma with 1-3 Prior Lines of Therapy

News Publication Date: May 29, 2026

Web References: http://dx.doi.org/10.1056/NEJMoa2603870

Image Credits: Sylvester Comprehensive Cancer Center

Keywords: Multiple myeloma, Teclistamab, bispecific antibody, immunotherapy, BCMA, T cells, hematologic malignancy, minimal residual disease, clinical trial, cancer immunotherapy, chemotherapy-free treatment, ASCO Annual Meeting

Emerging from a collaborative effort spearheaded by researchers at The Wistar Institute and Temple University, a novel metabolic pathway has been illuminated, offering a groundbreaking avenue to tackle ovarian cancers that are adept at DNA repair. The collaborative study, published in the prestigious journal Nature, reveals that alpha-ketoglutarate (αKG), a key metabolic intermediate, accumulates in DNA repair proficient ovarian tumors and plays an unexpected but crucial role in facilitating DNA repair. This discovery overturns conventional assumptions focused solely on αKG’s role in demethylation and opens an unprecedented window into metabolic regulation linked to genome maintenance.

The crux of this research hinges on αKG’s capacity to activate an enzyme called TMLHE, previously unassociated with DNA repair mechanisms. TMLHE catalyzes the initial step in the biosynthesis of carnitine, a metabolite widely recognized for its role in energy metabolism by transporting fatty acids into mitochondria. This metabolic axis—αKG to TMLHE to carnitine production—has now been implicated as a pivotal driver of histone acetylation, a modification that relaxes the tight packaging of DNA around histone proteins. This loosening of chromatin structure is essential for the DNA repair machinery to access and mend damaged genomic regions effectively.

Through the innovative application of CRISPR-based screening technology, the research team systematically identified TMLHE as the linchpin enzyme enabling αKG’s influence on DNA repair. This enzyme had been overlooked by the scientific community, which traditionally linked αKG’s functions exclusively to its role as a cofactor for demethylases. The revelation that TMLHE-mediated carnitine synthesis facilitates histone acetylation fundamentally shifts our understanding of metabolic regulation in cancer cells, underscoring a unique acetylation pathway independent of the known methylation pathways governed by αKG.

Carnitine’s newly discovered role transcends its classical function of mitochondrial fatty acid transport. It acts as a molecular courier, shuttling acetyl groups—key metabolic intermediates—out of mitochondria and into the cell nucleus. Within the nucleus, these acetyl groups are deposited onto histones via acetylation, thereby modulating chromatin accessibility. This biochemical maneuver is integral to efficient DNA repair, as it dictates the spatial dynamics of DNA repair complexes. By modulating histone acetylation, carnitine effectively orchestrates the structural environment necessary for repair proteins to rectify DNA lesions inflicted by chemotherapy.

Crucially, inhibition experiments targeting TMLHE or the carnitine biosynthesis pathway demonstrated a pronounced impairment in histone acetylation at critical chromatin sites. This biochemical blockade hinders the assembly of DNA repair machinery, sensitizing cancer cells to DNA-damaging chemotherapeutic agents such as platinum-based drugs. These findings hold significant therapeutic promise, suggesting that dual targeting of metabolic pathways and DNA repair mechanisms can synergistically overcome chemoresistance and improve clinical outcomes in ovarian cancer patients.

The translational potential of these insights was underscored by preclinical studies employing mildronate, a clinically tolerated inhibitor of carnitine synthesis. When administered concomitantly with cisplatin in mouse models, mildronate significantly curtailed tumor growth, whereas either agent alone elicited minimal effects. This combinatorial approach exemplifies a practical strategy to subvert DNA repair proficiency in tumors, advocating for clinical trials assessing carnitine synthesis inhibitors as adjuvants in chemotherapy regimens.

Further supporting the clinical relevance, patient-derived data revealed that elevated TMLHE expression in tumor biopsies correlated strongly with diminished progression-free survival following chemotherapy. Concurrently, higher serum levels of acetylcarnitine at diagnosis independently predicted accelerated disease progression, presenting an opportunity for biomarker-driven patient stratification. These findings hint at the feasibility of utilizing blood-based tests to identify ovarian cancer patients with treatment-resistant phenotypes and to tailor combination therapies accordingly.

The ramifications of this discovery extend far beyond ovarian cancer alone. Given that αKG is a central metabolic regulator and its levels decline with aging, the elucidated pathway offers a profound new lens through which to investigate gene regulation, genomic integrity, and cellular aging processes. Histone acetylation, modulated via αKG-driven carnitine metabolism, emerges as a vital nexus connecting metabolism to the maintenance of DNA stability, with far-reaching implications across cancer biology, stem cell research, and developmental biology.

This paradigm-shifting study was achieved through an exemplary interdisciplinary collaboration, weaving together expertise in metabolomics, biochemistry, molecular biology, and clinical oncology. The integration of advanced mass spectrometry, molecular genetics, and animal modeling facilitated the comprehensive mapping of the αKG-TMLHE-carnitine axis within cellular and patient tumor contexts. This collective effort epitomizes the power of scientific community and cross-institutional partnerships in addressing complex biomedical challenges.

Dr. Katherine Aird, the senior author and co-leader of the Molecular and Cellular Oncogenesis Program at Wistar, reflected on the unexpected nature of the findings: “Everyone in the field expected the focus to be on demethylases, but discovering TMLHE as a key player revealed an unanticipated metabolic mechanism driving DNA repair.” Nathaniel Snyder, co-senior author and expert in cardiovascular discovery at Temple University, emphasized the novelty of this distinct acetylation pathway controlled by αKG, highlighting its essential role in DNA repair—a biological insight hitherto unrecognized.

Collectively, these findings paint a vibrant portrait of metabolic control of epigenetic regulation, unveiling therapeutic vulnerabilities in chemoresistant ovarian cancers. By harnessing the power of metabolic intervention, there is now a tangible pathway to thwart the resilience of these aggressive tumors, offering renewed hope for patients facing limited treatment options. This advancement not only charts a new course in cancer therapy but also enriches our fundamental understanding of the intertwined nature of metabolism, epigenetics, and genome stability in human health and disease.

Subject of Research: Animals

Article Title: αKG-mediated carnitine synthesis drives DNA repair via histone acetylation

News Publication Date: 27-May-2026

Web References:

• Research Article: https://www.nature.com/articles/s41586-026-10584-7
• DOI: http://dx.doi.org/10.1038/s41586-026-10584-7

References:
Apoorva Uboveja et al., “αKG-mediated carnitine synthesis drives DNA repair via histone acetylation,” Nature, 2026.

Image Credits: The Wistar Institute

Keywords: Ovarian cancer, DNA damage responses, alpha-ketoglutarate, carnitine synthesis, histone acetylation, DNA repair, chemotherapy resistance, TMLHE enzyme, metabolic pathways, epigenetics, cancer metabolism, platinum-based chemotherapy

Cancer relapse poses a particularly stubborn obstacle in medulloblastoma due to the existence of a resilient subpopulation of tumor cells possessing stem cell-like properties. These cells can self-renew and persist even through aggressive treatment regimens. Unlike the bulk of tumor cells that proliferate rapidly and succumb to chemotherapy and radiation, these slow-dividing cells evade therapy by relying on alternative biological pathways that current treatments fail to disrupt. Dr. Blanco’s research illuminates this evasive subset as the critical driver behind tumor recurrence, emphasizing the necessity of targeting these relapse-initiating cells to achieve durable remission.

The study, recently published in the peer-reviewed journal Cell Death & Disease, explores an innovative approach to attenuate the stemness and relapse propensity of medulloblastoma cells by pharmacologically modulating a protein known as Casein Kinase 1 alpha (CK1α). CK1α plays an essential regulatory role within the tumor by influencing two pivotal cancer signaling pathways: Glioma-associated oncogene homolog (GLI) and the Wingless-related integration site (WNT) pathways. These pathways are central to tumor proliferation and self-renewal, respectively. Importantly, previous research by Dr. Blanco had identified GLI as a potential target to slow tumor growth; however, the current investigation expands this framework by addressing WNT signaling concurrently, enhancing the therapeutic potential.

The compound pyrvinium, an FDA-approved drug traditionally used as an anthelmintic agent, is repurposed in this study for cancer intervention due to its ability to activate CK1α. Activation of CK1α by pyrvinium effectively suppresses GLI-dependent signaling and simultaneously impairs WNT-driven self-renewal mechanisms. This dual inhibition disrupts the complex signaling networks that medulloblastoma stem-like cells exploit to survive and repopulate the tumor after initial treatment. Through preclinical models, the researchers demonstrated that pyrvinium could extend the time to relapse and reduce the overall risk of tumor recurrence, marking a significant advancement over monotherapy strategies targeting a single signaling axis.

This dual targeting addresses a fundamental challenge in cancer biology: the capability of malignant cells to adapt and escape when only one pathway is inhibited. By exerting pressure on multiple critical routes simultaneously, this approach minimizes the likelihood of tumor cells circumventing therapeutic effects and fosters a more robust and sustained anticancer response. Dr. Blanco emphasizes that this mechanism could account for the superior performance of CK1α agonists compared to previous single-pathway inhibitors, which often fail to eradicate the stem-like tumor cells responsible for relapse.

Despite these promising results, the researchers acknowledge that these findings represent an early breakthrough rather than a finalized treatment. One substantial hurdle impeding clinical translation is the limited ability of pyrvinium to cross the blood-brain barrier (BBB), a vital consideration in brain tumor therapy. To overcome this obstacle, the team developed a modified pyrvinium formulation designed to penetrate the BBB effectively. Preliminary data indicate encouraging efficacy in preclinical models, suggesting that with further refinement, this derivative could become a viable therapeutic option for pediatric brain tumor patients.

Beyond extending survival, this research holds profound implications for the quality of life of childhood cancer survivors. Current medulloblastoma treatments, while lifesaving, often inflict long-term developmental harm, including cognitive deficits and elevated risks of secondary malignancies. Dr. Blanco highlights the urgent need for treatments tailored specifically to pediatric tumors rather than adapted from adult protocols, as the latter frequently fail to address the unique biological and clinical nuances of childhood cancers while exposing young patients to harmful side effects.

The novel strategy of simultaneously targeting GLI and WNT pathways via CK1α activation shifts the paradigm in medulloblastoma treatment by confronting the cellular roots of relapse directly. By focusing on the tumor’s self-renewing core, researchers aim not merely to shrink tumors temporarily but to achieve lasting eradication and prevent the cancer’s deadly return. This fundamental shift offers transformative potential for improving outcomes in one of the most vulnerable patient populations.

Looking ahead, the path toward clinical application requires rigorous optimization of drug delivery mechanisms, ensuring safety and efficacy in pediatric patients. Dr. Blanco’s team plans to advance their CK1α agonist compounds through additional preclinical studies, honing in on formulations that maximize BBB permeability without compromising therapeutic potency. The ultimate goal is a new class of targeted treatments that offer hope where current options fall short, balancing efficacy with a minimal long-term burden on young survivors.

This research also opens avenues for broadening the therapeutic impact beyond medulloblastoma. Given the role of GLI and WNT pathways in various malignancies, CK1α agonists could become a versatile tool in oncology. The approach exemplifies the power of drug repurposing—leveraging existing FDA-approved drugs for novel indications—accelerating the transition from bench to bedside and potentially transforming cancer care landscapes.

In sum, Dr. Jezabel Rodriguez Blanco’s work elucidates a critical vulnerability in medulloblastoma’s relapse mechanism and pioneers a therapeutic strategy that tackles this challenge head-on. While clinical adoption remains on the horizon, these findings underscore the emerging shift toward precision medicine in pediatric oncology, where treatments are designed to interrupt the specific biology driving tumor recurrence. It is a hopeful stride toward changing what is often a tragic prognosis into a story of survival and renewed life for children afflicted by medulloblastoma.

Subject of Research: Cells

Article Title: CK1α agonists attenuate medulloblastoma stemness and relapse risk

News Publication Date: Not specified (article published 24-Apr-2026)

Web References:
http://dx.doi.org/10.1038/s41419-026-08762-6

Image Credits: Medical University of South Carolina

Keywords: Medulloblastoma, Brain cancer, Pediatrics, Cancer treatments, Cancer medication